What are the origins of growing microbial resistance? Both Lamarck and Darwin were right

References

• Ligon BL. Biography Louis Pasteur: A controversial figure in a debate on scientific ethics. Semin Pediatr Infect Dis. 2002;13(2):134–141.
   PubMedGoogle Scholar
• Schwartz M. Louis pasteur and molecular medicine: a centennial celebration. Mol Med. 1995;1(6):593–595.
   PubMed Web of Science ®Google Scholar
• Mitscher L, Pillai S, Gentry E, et al. Multiple drug resistance. Med Res Rev. 1999;19(6):477–496.
   PubMed Web of Science ®Google Scholar
• Blair J, Webber M, Baylay A, et al. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13(1):42–51. .
   PubMed Web of Science ®Google Scholar
• Stuart B, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med. 2004;10(12):122–129.
   Web of Science ®Google Scholar
• Zoulim F, Buti M, Lok A. Antiviral-resistant hepatitis B virus: can we prevent this monster from growing? J Viral Hepat. 2007;14(1):29–36.
   PubMedGoogle Scholar
• Livermore D. Bacterial Resistance: origins, epidemiology, and impact. Clin Infect Dis. 2003;36(1):11–23.
   Google Scholar
• Gaylord G. Lamarck, Darwin and butler: three approaches to evolution. Am Scholar. 1961;30(2):238–249.
   Web of Science ®Google Scholar
• Mayr E. Lamarck revisited. J Hist Biol. 1972;5(1):55–94.
   PubMedGoogle Scholar
• Balter M. Was Lamarck just a little bit right? Sci. 2000;228(5463):38.
   Google Scholar
• Penny D. Epigenetics, Darwin, and Lamarck. Genome Biol Evol. 2015;7(6):1758–1760. .
   PubMed Web of Science ®Google Scholar
• Howard ST, Byrd TF. The rapidly growing mycobacteria: saprophytes and parasites. Microbes Infect. 2000;2(15):1845–1853.
   PubMed Web of Science ®Google Scholar
• Knothe H, Shah P, Krcmery V, et al. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection. 1983;11(6):315–317. .
   PubMed Web of Science ®Google Scholar
• Russell A, Tattawasart U, Maillard J, et al. Possible link between bacterial resistance and use of antibiotics and biocides. Antimicrob Agents Chemother. 1998;42(8):2151. .
   PubMed Web of Science ®Google Scholar
• Jain R, Rivera M, Lake J. Horizontal gene transfer among genomes: the complexity hypothesis. Proc Natl Acad Sci USA. 1999;96(7):3801–3806.
   PubMed Web of Science ®Google Scholar
• Gyles C, Boerlin P. Horizontally transferred genetic elements and their role in pathogenesis of bacterial disease. Vet Pathol. 2013;51(2):328–340.
   PubMed Web of Science ®Google Scholar
• Ma N, Isaacs F. Genomic recoding broadly obstructs the propagation of horizontally transferred genetic elements. Cell Syst. 2016;3(2):199–207.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Itoh T, Matsuda H, et al. Biased biological functions of horizontally transferred genes in prokaryotic genomes. Nat Genet. 2004;36(7):760–766. .
   PubMed Web of Science ®Google Scholar
• Battegay M, Flückiger U. Der Wert der klinischen Infektiologie. Internist (Berl). 2005;46(6):623–629.
   PubMedGoogle Scholar
• Nikaido H, Vaara M. Molecular basis of bacterial outer membrane permeability. Microbiol Rev. 1985;49(1):1–32.
   PubMedGoogle Scholar
• Chopra I, Roberts M. Tetracycline Antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001;65(2):232–260.
   PubMed Web of Science ®Google Scholar
• Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev. 2003;67(4):593–656.
   PubMed Web of Science ®Google Scholar
• Hu Y, Shamaei-Tousi A, Liu Y, et al. A new approach for the discovery of antibiotics by targeting non-multiplying bacteria: a novel topical antibiotic for staphylococcal infections. PLoS ONE. 2010;5(7):11818. .
   Web of Science ®Google Scholar
• Campbell LL, Williams OB. The effect of temperature on the nutritional requirements of facultative and obligate thermophilic bacteria. J Bacteriol. 1953;65(2):141–145.
   PubMed Web of Science ®Google Scholar
• Hamscher G, Sczesny S, Höper H, et al. Determination of persistent tetracycline residues in soil fertilized with liquid manure by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry. Anal Chem. 2002;74(7):1509–1518. .
   PubMed Web of Science ®Google Scholar
• Kümmerer K. Resistance in the environment. J Antimicrob Chemother. 2004;54(2):311–320.
   PubMed Web of Science ®Google Scholar
• Boor K. Bacterial stress responses: what doesn’t kill them can make them stronger. PLoS Biol. 2006;4(1):0018–20.
   Web of Science ®Google Scholar
• Keith P. Bacterial stress responses as determinants of antimicrobial resistance. J Antimicrob Chemother. 2012;67(9):2069–2089.
   PubMed Web of Science ®Google Scholar
• MacFadden D, McGough S, Fisman D, et al. Antibiotic resistance increases with local temperature. Open Forum Infect Dis. 2017;4(1):179. .
   Google Scholar
• Barancheshme F, Munir M. Strategies to combat antibiotic resistance in the wastewater treatment plants. Front Microbiol. 2018;17(8):2603.
   Google Scholar
• Suzuki H, Taketani T, Kobayashi J, et al. Antibiotic resistance mutations induced in growing cells of Bacillus-related thermophiles. J Antibiot. 2018;71(3):382–389. .
   PubMed Web of Science ®Google Scholar
• Georgopapadakou N, Smith S, Sykes R. Penicillin-binding proteins in Bacteroides fragilis. J Antibiot. 1983;36(7):907–910.
   PubMed Web of Science ®Google Scholar
• Lukačlšinová M, Novak S, Paixão T. Stress-induced mutagenesis: stress diversity facilities the persistence of mutator genes. PLoS Comput Biol. 2017;13(7):e1005609.
   PubMed Web of Science ®Google Scholar
• Leon O, Panos C. Differences in penicillin-binding proteins of Streptococcus pyogenes and two derived, stabilized L forms. J Bacteriol. 1988;10(170):4775–4783.
   Google Scholar
• Mendelman P, Chaffin D. PBP profiles of Haemophilus influenzae, H. aegyptius, and the H. influenzae biogroup aegyptius associated with brazilian purpuric fever. Diagn Microbiol Infect Dis. 1989;12(5):445–447.
   PubMed Web of Science ®Google Scholar
• Musser J. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev. 1995;8(4):496–514.
   PubMed Web of Science ®Google Scholar
• Henze U, Berger-Bachi B. Staphylococcus aureus penicillin-binding protein 4 and intrinsic β-lactam resistance. Antimicrob Agents Chemother. 1995;39(11):2415–2422.
   PubMed Web of Science ®Google Scholar
• Cosgrove D. Relaxation in a high-stress environment: the molecular bases of extensible cell walls and cell enlargement. Plant Cell. 1997;9(7):1031–1041.
   PubMed Web of Science ®Google Scholar
• Wagner P, Waldor M. Bacteriophage control of bacterial virulence. Infect Immun. 2002;70(8):3985–3993.
   PubMed Web of Science ®Google Scholar
• Nelson D, Young K. Contributions of PBP 5 and DD-Carboxypeptidase penicillin binding proteins to maintenance of cell shape in Escherichia coli. J Bacteriol. 2001;183(10):3055–3064.
   PubMed Web of Science ®Google Scholar
• Stewart P, Costerton J. Antibiotic resistance of bacteria in biofilms. Lancet. 2001;358(9276):135–138.
   PubMed Web of Science ®Google Scholar
• Sulakvelidze A, Alavidze Z, Morris G. Bacteriophage therapy. Antimicrob Agents Chemother. 2001;45(3):649–659.
   PubMed Web of Science ®Google Scholar
• Schweizer H. Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions. Genet Mol Res. 2003;2(1):48–62.
   PubMedGoogle Scholar
• Rodríguez J, Navarro M, Romero L, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol. 2004;42(3):1089–1094. .
   PubMed Web of Science ®Google Scholar
• Hastings P, Rosenberg S, Slack A. Antibiotic-induced lateral transfer of antibiotic resistance. Trends Microbiol. 2004;12(9):401–404.
   PubMed Web of Science ®Google Scholar
• Bertsche U, Breukink E, Kast T, et al. In vitro murein (peptidoglycan) synthesis by dimers of the bifunctional transglycosylase-transpeptidase PBP1b from Escherichia coli. J Biol Chem. 2005;280(45):38096–38101.
   PubMed Web of Science ®Google Scholar
• Hujer A, Kania M, Gerken T, et al. Structure-activity relationships of different beta-lactam antibiotics against a soluble form of Enterococcus faecium PBP5, a type II bacterial transpeptidase. Antimicrob Agents Chemother. 2005;49(2):612–618. .
   PubMed Web of Science ®Google Scholar
• Paterson D, Bonomo R. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657–686.
   PubMed Web of Science ®Google Scholar
• Walsh T, Toleman M, Poirel L, et al. Metallo-β-lactamases: the quiet before the storm? Clin Microbiol Rev. 2005;18(2):306–325. .
   PubMed Web of Science ®Google Scholar
• Tenover F. Mechanisms of antimicrobial resistance in bacteria. Am J Med. 2006;119(6):3–10.
   PubMed Web of Science ®Google Scholar
• Sauvage E, Kerff F, Terrak M, et al. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiol Rev. 2008;32(2):234–258. .
   PubMed Web of Science ®Google Scholar
• Martínez J. Antibitics and antibitics resistance genes in natural environments. Science. 2008;321(5887):365–367.
   PubMed Web of Science ®Google Scholar
• Bo L, Mihai P. ARDB—antibiotic resistance genes database. Nucleic Acids Res. 2009;37(1):443–447.
   Google Scholar
• Labrie S, Samson J, Moineau S. Bacteriophage resistance mechanisms. Nat Rev Microbiol. 2010;8(5):317–327.
   PubMed Web of Science ®Google Scholar
• Høiby N, Bjarnsholt T, Givskov M, et al. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35(4):322–332. .
   PubMed Web of Science ®Google Scholar
• Cayo R, Rodríguez MC, Espinal P, et al. Analysis of genes encoding penicillin-binding proteins in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 2011;55(12):5907–5913. .
   PubMed Web of Science ®Google Scholar
• van Hoek A, Mevius D, Guerra B, et al. Acquired antibiotic resistance genes: an overview. Front Microbiol. 2011;2(203):1–27. .
   PubMedGoogle Scholar
• Colomer-Lluch M, Jofre J, Muniesa M. Antibiotic resistance genes in the bacteriophage DNA fraction of environmental samples. PLoS One. 2011;6(3):17549.
   PubMed Web of Science ®Google Scholar
• Popowska M, Rzeczycka M, Miemik A, et al. Influence of soil use on prevalence of tetracycline, streptomycin, and erythromycin resistance and associated resistance genes. Antimicrob Agents Chemother. 2012;56(3):1434–1443. .
   PubMed Web of Science ®Google Scholar
• Condell O, Iversen C, Cooney S, et al. Efficacy of biocides used in the modern food industry to control salmonella enterica, and links between biocide tolerance and resistance to clinically relevant antimicrobial compounds. Appl Environ Microbiol. 2012;78(9):3087–3097. .
   PubMed Web of Science ®Google Scholar
• Sun S, Selmer M, Andersson D. Resistance to β-lactam antibiotics conferred by point mutations in penicillin-binding proteins PBP3, PBP4 and PBP6 in Salmonella enterica. PLoS One. 2014;9(5):97202.
   PubMed Web of Science ®Google Scholar
• Carlet J, Jarlier V, Harbarth S, et al. Ready for a world without antibiotics? The pensières antibiotic resistance call to action. Antimicrob Resist Infect Control. 2012;1(11):1–13. .
   PubMedGoogle Scholar
• Goldstein B. Resistance to rifampicin: a review. J Antibiot. 2014;67(9):625–630.
   PubMed Web of Science ®Google Scholar
• Oldfield E, Feng X. Resistance-resistant antibiotics. Trends Pharmacol Sci. 2014;35(12):664–674.
   PubMed Web of Science ®Google Scholar
• von Wintersdorff C, Penders J, van Niekerk J, et al. Dissemination of antimicrobial resistance in microbial ecosystems through horizontal gene transfer. Front Microbiol. 2016;7(173):1–10. .
   PubMedGoogle Scholar
• Du D, Wang-Kan X, Neuberger A. Multidrug efflux pumps: structure, function and regulation. Nat Rev Microbiol. 2018;16(9):523–539.
   PubMed Web of Science ®Google Scholar
• Sia I, Wieland M. Current concepts in the management of Tuberculosis. Mayo Clin Proc. 2011;86(4):348–361.
   PubMed Web of Science ®Google Scholar
• Fouad M, Rodriguez da Silva J, Galvão A, et al. Tuberculosis treatment. J Bras Pneumol. 2017;43(6):472–486. .
   PubMed Web of Science ®Google Scholar
• Bansal R, Sharma D, Singh R. Tuberculosis and its treatment: an overview. Mini Rev Med Chem. 2018;18(1):58–71.
   PubMed Web of Science ®Google Scholar
• Myers JA. The natural history of Tuberculosis in the human body: forty-five years of observation. JAMA. 1965;194(10):1086–1092.
   PubMed Web of Science ®Google Scholar
• Palomino J, Martin A. TMC207 becomes bedaquiline, a new anti-TB drug. Future Microbiol. 2013;8(9):1071–1080.
   PubMed Web of Science ®Google Scholar
• Mahajan R. Bedaquiline: first FDA-approved tuberculosis drug in 40 years. Int J Appl Basic Med Res. 2013;3(1):1.
   PubMedGoogle Scholar
• Kakkar A, Dahiya N. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls. Tuberculosis. 2014;94(4):357–362.
   PubMed Web of Science ®Google Scholar
• Goel D. Bedaquiline: A novel drug to combat multiple drug-resistant tuberculosis. J Pharmacol Pharmacother. 2014;5(1):77.
   Google Scholar
• Akiba T, Yokota T, Tamura N. Mutagenic effect of streptomycin on bacteria. Japan J Microb. 1957;1(3):197–204. .
   PubMedGoogle Scholar
• Fatima R, Ashraf M, Ejaz S, et al. In vitro toxic action potential of anti tuberculosis drugs and their combinations. Environ Toxicol Pharmacol. 2013;36(2):501–513. .
   PubMed Web of Science ®Google Scholar
• Houston S, Fanning A. Current and potential treatment of tuberculosis. Drugs. 1994;48(5):689–708.
   PubMed Web of Science ®Google Scholar
• Davies P, Yew WW. Recent developments in the treatment of tuberculosis. Expert Opin. Investig Drugs. 2003;12(8):1297–1312. .
   PubMed Web of Science ®Google Scholar
• Chan E, Iseman M. Current medical treatment for tuberculosis. BMJ. 2002;325(7375):1282–1286.
   PubMed Web of Science ®Google Scholar
• Thomas M. The history of tuberculosis. Respir Med. 2006;100(11):1862–1870.
   PubMed Web of Science ®Google Scholar
• Zellweger JP. Treatment of tuberculosis. Expert Rev Respir Med. 2007;1(1):85–97.
   PubMedGoogle Scholar
• Cardona PJ. Revisiting the natural history of tuberculosis. Arch. Immunol Ther Exp. 2010;58(1):7–14. .
   PubMed Web of Science ®Google Scholar
• Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2012;16(4):447–454.
   PubMed Web of Science ®Google Scholar
• Keshavjee S, Farmer P. Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med. 2012;367(10):931–936.
   PubMed Web of Science ®Google Scholar
• Horsburgh C, Barry E, Lange C. Treatment of tuberculosis. N Eng J Med. 2015;373(22):2149–2160.
   PubMed Web of Science ®Google Scholar
• Sotgiu G, Pontali E, Centis R, et al. Delamanid (OPC-67683) for treatment of multi-drugresistant tuberculosis. Expert Rev Anti Infect Ther. 2015;13(3): 305–315. .
   PubMed Web of Science ®Google Scholar
• Zuur M, Bolhuis M, Anthony R, et al. Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis. Expert Opin Drugs Metabol Toxicol. 2016;12(5)509–521. .
   PubMed Web of Science ®Google Scholar
• Hofman S, Segers M, Ghimire S, et al. Emerging drugs and alternative possibilities in the treatment of tuberculosis. Expert Opin Emerging Drugs. 2016;21(1):103–116. .
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang S, Cui P, et al. Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2017;72(12):3272–3276. .
   PubMed Web of Science ®Google Scholar
• Dookie N, Rambaran S, Padayatchil N. Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care. J Antimicrob Chemother. 2018;73(5):1138–1151.
   PubMed Web of Science ®Google Scholar
• Gong W, Liang Y, Wu X. The current status, challenges, and future developments of new tuberculosis vaccines. Human Vaccines Immunotherapeutics. 2018;14(7):1697–1716. .
   PubMed Web of Science ®Google Scholar
• Lange C, Chesov D, Heyckendorf J. Drug-resistant tuberculosis: an update on disease burden, diagnosis and treatment. Respirology. 2018;23(7):656–673.
   PubMed Web of Science ®Google Scholar
• Prasanna A, Niranjan V. Classification of Mycobacterium tuberculosis DR, MDR,XDR isolates and identification of signature mutationpattern of drug resistance. Bioinformation. 2019;15(4):261–268.
   PubMed Web of Science ®Google Scholar
• Wen S, Jing W, Zhang T, et al. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis. 2019;38(7):1293–1296. .
   PubMed Web of Science ®Google Scholar
• de Wet T, Warner D, Mizrahi V. Harnessing biological Insight to accelerate tuberculosis drug discovery. Acc Chem Res. 2019;52(8):2340–2348.
   PubMed Web of Science ®Google Scholar
• Shah I, Poojari V, Meshram H. Multi-drug resistant and extensively-drug resistant tuberculosis. Indian J Pediatrics. 2020;87(10):833–839. .
   PubMed Web of Science ®Google Scholar
• Lacobino A, Fattorini L, Giannoni F. Drug-Resistant Tuberculosis 2020: where We. Stand Appl Sci. 2020;10(6):2153. .
   Google Scholar
• Alffenaar J, Akkerman O, Kim H. Precision and personalized medicine and anti-TB treatment: is TDM feasible for programmatic use? Int J Infect Dis. 2020;92:5–9.
   Web of Science ®Google Scholar
• Rossato D, de Queiroz F, Battista G. Shortened tuberculosis treatment regimens: what is new? J Bras Pneumol. 2020;46(2):1–8.
   Web of Science ®Google Scholar
• Lee A, Xie Y, Barry C. Current and future treatments for tuberculosis. BMJ. 2020;2(368):216.
   Google Scholar
• Bard. The next evolutionary synthesis: from Lamarck and Darwin to genomic variation and systems biology. Cell Commun Signaling. 2011;9,30.
   PubMedGoogle Scholar
• Liu Q, Wei J, Li Y, et al. Mycobacterium tuberculosis clinical isolates carry mutational signatures of host immune environments. Sci Adv. 2020;6(22):eaba4901. .
   PubMed Web of Science ®Google Scholar
• McGrath M, Gey van Pittius N, van Helden P, et al. Mutation rate and the emergence of drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2014;69(2):292–302. .
   PubMed Web of Science ®Google Scholar
• Aly F, Donya S. In vivo antimutagenic effect of vitamins C and E against rifampicin-induced chromosome aberrations in mouse bone-marrow cells. Mutat Res. 2002;518(1):1–7.
   PubMed Web of Science ®Google Scholar
• Blanco M, Martínez A, Urios A, et al. Detection of oxidative mutagenesis by isoniazide and other hydrazine derivatives in Escherichi coli WP2 tester strain IC203, deficient in OxyR: strong protective effects of rat liver S9. Mutat Res. 1998;417(1):39–46. .
   PubMed Web of Science ®Google Scholar
• Wade D, Lohman P, Mattern I, et al. The mutagenicity of isoniazid in Salmonella and its effects on DNA repair and synthesis in human fibroblasts. Mutat Res. 1981;89(1):9–20. .
   PubMedGoogle Scholar
• Sharmada S, Avraneel P, Atul P, et al. Mycobacterium smegmatis moxifloxacin persister cells produce high levels of hydroxyl radical, generating genetic resisters selectable not only with moxifloxacin, but also with ethambutol and isoniazid. Micro Soc. 2019;166(2):180–198.
   Web of Science ®Google Scholar